Candesartan shown to be safe new therapy for genetic heart disease
Mylan Inc. has confirmed that the company and its subsidiary, Mylan Pharmaceuticals Inc., have been sued by Novartis in connection with Fluvastatin Capsules USP, 20 mg (base) and 40 mg (base), the generic version of Novartis’ Lescol(R) Capsules. Mylan believes it is the first company to file a substantially complete Abbreviated New Drug Application
Full Post: Mylan confirms generic Lescol patent challenge
A new clinical trial suggests that long-term use of candesartan, a drug currently used to treat hypertension, may significantly reduce the symptoms of genetic heart disease.
The related report by Penicka et al, “The effects of candesartan on left ventricular hypertrophy and function in non-obstructive hypertrophic cardiomyopathy: a pilot, randomized study,” appears in the January issue of The Journal of Molecular Diagnostics.
Hypertrophic cardiomyopathy, or HCM, is a genetic heart disease where the heart muscle is thickened, especially in the left ventricle. Although people with HCM usually display mild symptoms or are completely asymptomatic, up to 1% of affected people succumb to sudden cardiac death (SCD), often with no previous signs of illness. HCM can be caused by mutations in a number of different genes, and different gene mutations may result in more or less severe symptoms.
Researchers lead by Dr. Jiri Krupicka of Na Homolce Hospital, Prague conducted a double-blind, placebo-controlled, randomized study on the long-term administration of candesartan in patients with HCM. Dr. Krupicka’s group found that candesartan reduced the symptoms of HCM, including decreasing the thickening of the left ventricle. This effect was found to be dependent on the underlying gene mutations in each patient. They did not observe any adverse effects of candesartan use over the course of their study.
These data suggest that effectiveness of angiotensin II receptor blockers, such as candesartan, on HCM may vary depending on the nature of the causative mutation and that the treatment protocol, therefore, should be customized to individual patients. Future studies in Dr. Penicka’s group will extend this pilot trial to more patients to confirm the current findings and to identify the mechanism by which candesartan improves left ventricle thickening.
Dr Andrew Whitten, Dr Cy Jeffries and Professor Jill Trewhella, from the School of Molecular and Microbial Biosciences, University of Sydney, with Samantha Harris, from the University of California, USA, have the first data showing how a protein in heart muscle cells works to maintain regular heart function. The research, published in the Proceedings of
Full Post: First study showing how protein fine-tunes the heart
Researchers at the University of Utah are enrolling people in a new clinical trial that uses a patient’s own stem cells to treat ischemic and non-ischemic heart failure. The one-year Cardiac Repair Cell Treatment of Patients with Dilated Cardiomyopathy (IMPACT-DCM) study will look at the safety of injecting Cardiac Repair Cells (CRC) and their ability
Full Post: Scientists use patient’s own stem cells to treat heart failure
Researchers at the Burnham Institute for Medical Research have shown in both fruit flies and humans that genes involved in embryonic heart development are also integral to adult heart function. The study, led by Rolf Bodmer, Ph.D., was published in Proceedings of National Academy of Sciences. Dr. Bodmer’s lab has discovered that in the fruit
Full Post: Fruit flies provide better understanding of human heart disease
The use of cardiopulmonary bypass does not cause short-term neurological problems in children and teenagers after surgery for less complex heart defects, according to pediatric researchers. The new finding contrasts favorably with previous studies that showed adverse neurological effects after newborn surgery for more complex heart conditions. “This is good news for school-aged children who
Full Post: Cardiopulmonary bypass for child heart surgery does not affect IQ
Even younger adults who have few short-term risk factors for heart disease may have a higher risk of developing heart disease over their lifetimes, according to new findings by a UT Southwestern Medical Center researcher. The findings, based on clinical studies and appearing in the Jan. 19 issue of the journal Circulation: Journal of the
Full Post: Researchers find that healthy, younger adults could be at risk for heart disease